In 2024, Ipsen's return on assets (ROA) was 0.1, a -11.78% increase from the 0.12 ROA in the previous year.

Ipsen Aktienanalyse

What does Ipsen do?

Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Ipsen's Return on Assets (ROA)

Ipsen's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Ipsen's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Ipsen's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Ipsen’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Ipsen stock

What is the Return on Assets (ROA) of Ipsen this year?

The Return on Assets (ROA) of Ipsen is 0.1 undefined this year.

What was the ROA of Ipsen compared to the previous year?

The ROA of Ipsen has increased by -11.78% compared to the previous year.

What consequences do high ROA have for investors of Ipsen?

A high ROA is advantageous for investors of Ipsen, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Ipsen?

A low ROA can be unfavorable for investors of Ipsen as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Ipsen affect the company?

An increase in ROA of Ipsen can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Ipsen impact the company?

A reduction in the ROA of Ipsen can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Ipsen?

Some factors that can influence the ROA of Ipsen include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Ipsen important for investors?

The ROA of Ipsen is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Ipsen take to improve ROA?

To improve ROA, Ipsen can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Ipsen pay?

Over the past 12 months, Ipsen paid a dividend of 1.2 EUR . This corresponds to a dividend yield of about 1.06 %. For the coming 12 months, Ipsen is expected to pay a dividend of 1.4 EUR.

What is the dividend yield of Ipsen?

The current dividend yield of Ipsen is 1.06 %.

When does Ipsen pay dividends?

Ipsen pays a quarterly dividend. This is distributed in the months of June, June, July, June.

How secure is the dividend of Ipsen?

Ipsen paid dividends every year for the past 24 years.

What is the dividend of Ipsen?

For the upcoming 12 months, dividends amounting to 1.4 EUR are expected. This corresponds to a dividend yield of 1.24 %.

In which sector is Ipsen located?

Ipsen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ipsen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ipsen from 6/3/2024 amounting to 1.2 EUR, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.

When did Ipsen pay the last dividend?

The last dividend was paid out on 6/3/2024.

What was the dividend of Ipsen in the year 2023?

In the year 2023, Ipsen distributed 1.2 EUR as dividends.

In which currency does Ipsen pay out the dividend?

The dividends of Ipsen are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ipsen stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ipsen

Our stock analysis for Ipsen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ipsen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.